18F-FDG PET/CT for predicting outcomes of diffuse large B-cell lymphoma：shall it be performed in the interim versus later phase of chemotherapy?
10.3969/j.issn.1673-4254.2015.02.10
- VernacularTitle:弥漫大B细胞淋巴瘤化疗中后期用18F-FDG PET/CT显像预测预后是否优于化疗中期？
- Author:
Huizhi LI
1
;
Hubing WU
;
Quanshi WANG
;
Hongsheng LI
;
Wenlan ZHOU
;
Ying TIAN
;
Ye DONG
Author Information
1. 南方医科大学南方医院PET中心
- Keywords:
diffuse large B-cell lymphoma;
chemotherapy;
emission-computed tomography;
X-ray computed;
prognosis prediction
- From:
Journal of Southern Medical University
2015;(2):208-212
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the value of 18F-FDG PET/CT performed in the interim and later phase of chemotherapy in predicting the prognosis of diffuse large B-cell lymphoma (DLBCL). Methods 18F-FDG PET/CT was performed in 71 patients with DLBCL in the interim phase of chemotherapy (3-4 cycles) and in another 71 patients in the later phase of chemotherapy (5-8 cycles). The patients were followed up for an average of 28.73 months (18-114 months) to compare the progression-free survival (PFS) and the PFS rate. Results The positive finding rate was similar between 18F-FDG PET/CT performed in the interim and the later phase (36.6%vs 33.8%,χ2=12.423, P>0.05). The PFS was much longer in patients with negative findings than in those with positive findings in both the interim (63.56 vs 19.23 months, P=0.000) and later phase groups (65.78 vs 24.32 months, P=0.000), but showed no significant difference between the negative patients (P>0.05) or between the positive patients (P>0.05) in the two groups. The PFS rate was significantly greater in patients with negative than those with positive findings in the interim group (73.3%vs 15.4%, P=0.000) and in the later phase group (74.5%vs 16.7%, P=0.000), but comparable between the negative (P>0.05) and between the positive patients (P>0.05) in the two groups. Conclusions 18F-FDG PET/CT in the interim and later phase of chemotherapy has similar value for predicting the prognosis of DLBCL, and we therefore recommend that 18F-FDG PET/CT be performed in the interim but not in the later phase.
